Back

Real-world effectiveness of glp-1 receptor agonists in older adults: concordant shifts in obesity and glycaemic categories

30 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Obesity and coronary microvascular dysfunction Obesity ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Associate Professor Ronen Arbel

Clalit Health services, Tel Aviv (Israel)

5 More presentations in this session

Presentation thumbnail
Obesity modifies the prognostic value of serially measured laboratory values in a real-world HFpEF cohort
Ms E. Hatip Unlu (Rotterdam, NL)
Abstract Slides Video
Presentation thumbnail
Metabolic health modifies SYNTAX II–Based revascularization risk beyond body mass index
Professor R. Abo Fanne (Hadera, IL)
Abstract Slides Video
Presentation thumbnail
Gaps in obesity diagnosis and management among australians admitted with cardiovascular disease: a multi-centre audit
Doctor M. Lim (Gold Coast, AU)
Abstract Slides Video
Presentation thumbnail
Central adiposity outperforms body mass index in predicting coronary artery disease: a prospective comparative study
Doctor G. Bettencourt Abreu (Funchal, PT)
Abstract Slides Video
Presentation thumbnail
Roles of weight change from early to middle adulthood and BMI in relation to cardiometabolic disease risks: findings from the China Kadoorie Biobank
Miss Y. Chen (Oxford, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Obesity and coronary microvascular dysfunction

The Event

Event poster

ESC Congress 2026

30 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Glucagon-like peptide-1 receptor agonists and outcomes in heart failure with preserved ejection fraction and obesity: a real-world systematic review and meta-analysis of observational studies
28 August 2026
thumbnail
Congress Presentation
Age-related patterns of medical therapy in diabetic patients with cardiovascular disease
28 August 2026
thumbnail
Congress Presentation
Cardiovascular outcomes across GLP-1/GIP agonists in a large, diverse real-world cohort: the INCRETIN-CV study
29 August 2026
thumbnail
Congress Presentation
State-of-the-art lecture on repurposing of diabetic medications: the new cure for all evils?
2 September 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources